Company Overview
Wockhardt Limited reported significant financial turnaround for FY 2025-26 with standalone net profit of ₹317 crore compared to a loss of ₹12 crore in FY25, driven by operational improvements and a ₹35 crore settlement gain from Dr. Reddy's Laboratories. The company convened its 27th Annual General Meeting on August 10, 2026, seeking shareholder approval for multiple resolutions including a ₹3000 crore capital raise through QIP/other securities.
Financial Performance
Standalone Results (FY26): Revenue from operations increased to ₹1,739 crore (₹1,402 crore in FY25) with profit before exceptional items and tax of ₹292 crore versus loss of ₹12 crore. Exceptional items included net gain of ₹25 crore from settlements. The company maintained gross block of PPE at ₹2,495 crore while significantly increasing intangible assets under development to ₹1,276 crore, primarily for New Chemical Entities (NCEs).
Capital Structure & Borrowings: Total borrowings stood at ₹2,125 crore with secured term loans from banks at ₹769 crore and unsecured loans from related parties of ₹748 crore. The adjusted net debt-to-equity ratio was 0.40 with total equity of ₹3,084 crore.
Significant Corporate Events
US Subsidiaries Deconsolidation: Wockhardt filed for voluntary Chapter 7 bankruptcy for Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC, resulting in deconsolidation effective July 11, 2025. This generated a net exceptional charge of ₹110 crore with assets derecognized including inventories (₹6 crore), trade receivables (₹106 crore), and goodwill (₹97 crore).
AGM Proposals: Key resolutions included revision of Executive Chairman Dr. Habil Khorakiwala's remuneration up to ₹15 crore annually, appointment of Ms. Zahabiya Khorakiwala as Executive Co-chairperson of Wockhardt Bio AG, approval of related party transactions aggregating ₹2100 crore, and modification of QIP proceeds utilization from biosimilar to broader R&D activities including NCEs.
Risk Management & Contingencies
Financial Risk Exposure: The company maintained significant foreign exchange exposure with GBP (₹256 crore), USD (₹424 crore), and EUR (₹3 crore). A 5% currency movement would impact P&L by ₹24 crore. Credit risk concentration showed Wockhardt Bio AG accounting for 69% of trade receivables.
Contingent Liabilities: Total contingent liabilities stood at ₹675 crore including income tax demands (₹345 crore disputed), sales tax/GST demands (₹117 crore disputed), NPPA demands (₹136 crore disputed), and various other regulatory claims.
Research & Development
Capital expenditure on R&D totaled ₹320 crore for FY26 with revenue expenditure of ₹125 crore. The company capitalized ₹317 crore on intangible development primarily for NCE programs including NCE 5222 (₹901 crore), NCE 4282 (₹245 crore), and NCE 6777 (₹129 crore).
Governance & Compliance
The annual report confirmed compliance with SEBI Listing Regulations and Companies Act 2013, with board composition including 9 directors (5 independent). Corporate Social Responsibility activities included ₹0.80 crore contribution to Wockhardt Foundation for healthcare initiatives.
Outlook
The capital raising initiative of ₹3000 crore aims to support business purposes including capex, R&D, debt repayment, and general corporate purposes, positioning the company for continued growth in pharmaceutical and biotech segments while managing its restructured operational footprint.